Pacira Biosciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Pacira BioSciences, Inc. announces its 2025 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and stock incentive plan approval.
NASDAQ
Pacira BioSciences achieved record revenue of $701 million in 2024 and made significant progress in clinical and regulatory developments.
NASDAQ
Pacira BioSciences reaffirms its commitment to enhancing shareholder value through a new $300 million share repurchase program and a focus on operational efficiency and margin expansion.
NASDAQ
DEFA14A: Pacira BioSciences Reaffirms Commitment to Shareholders with $300 Million Share Repurchase Program
Pacira BioSciences announces a $300 million share repurchase program and reinforces its confidence in its 5x30 strategic plan to enhance shareholder value.
NASDAQ
Pacira BioSciences confirms receipt of director nominations from DOMA Perpetual Capital Management and states that no shareholder action is required at this time.
NASDAQ
Pacira BioSciences announces its 2024 Annual Meeting of Stockholders to be held on June 11, 2024, with key proposals including the election of directors, ratification of KPMG as the independent auditor, and advisory vote on executive compensation.
NASDAQ
Pacira BioSciences outlines its strategic focus for 2024, positioning itself for significant growth in 2025 and beyond by reshaping its executive team, reallocating resources, and prioritizing investments.